Court Finds Advanced Cell Diagnostics Patents Invalid in Lawsuit with Molecular Instruments [Yahoo! Finance]
Bio-Techne Corp (TECH)
Last bio-techne corp earnings: 4/30 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.bio-techne.com
Company Research
Source: Yahoo! Finance
Wales has found two patents owned by Advanced Cell Diagnostics, Inc. (a Bio-Techne group company) to be invalid. In a 2022 lawsuit filed in the United Kingdom (proceedings no. HP-2022-000026), Advanced Cell Diagnostics alleged that Molecular Instruments' HCR™ RNA-ISH technology infringes European Patents (UK) 2,500,439 and 1,910,572. The Court has rejected that claim ruling that both patents are invalid ( https://caselaw.nationalarchives.gov.uk/ewhc/pat/2024/898 ) with Mr. Justice Meade finding that Molecular Instruments' primary evidence (on invalidity) is "really overwhelming in this case." "Our goal is to empower biologists, bioengineers, drug developers, and diagnostics developers by providing them with next-generation molecular tools that enable breakthroughs in their projects," said Dr. Harry Choi, CEO of Molecular Instruments. "We felt compelled to fight this lawsuit to protect the ability of our customers to continue their research, as many customers working in challenging
Show less
Read more
Impact Snapshot
Event Time:
TECH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TECH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TECH alerts
High impacting Bio-Techne Corp news events
Weekly update
A roundup of the hottest topics
TECH
News
- Bio-Techne Co. (NASDAQ: TECH) had its "buy" rating re-affirmed by analysts at Benchmark Co.. They now have a $95.00 price target on the stock.MarketBeat
- Bio-Techne Corporation (NASDAQ:TECH) Q3 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Bio-Techne Co. (NASDAQ: TECH) had its price target raised by analysts at Robert W. Baird from $73.00 to $81.00. They now have an "outperform" rating on the stock.MarketBeat
- Bio-Techne Corporation (NASDAQ:TECH) Shares Could Be 25% Above Their Intrinsic Value Estimate [Yahoo! Finance]Yahoo! Finance
- Bio-Techne beats third-quarter estimates on improving demand for biotech products [Reuters]Reuters
TECH
Earnings
- 5/1/24 - Beat
TECH
Sec Filings
- 5/3/24 - Form 4
- 5/3/24 - Form 3
- 5/1/24 - Form 8-K
- TECH's page on the SEC website